NeoGenomics, Inc. (NEO): Are There Still Some Opportunities On The Horizon

NeoGenomics, Inc. (NASDAQ:NEO) trade is getting exciting but lets take a deeper look whether it is as good a moment. Now trading with a market value of 935.23M, the company has a mix of catalysts and obstacles that spring from the nature of its operations. As the day-to-day narrative ebbs and flows for this company, it is more important than ever to step back and get a bird’s eye view of the fundamental reality under the surface of this story.

NeoGenomics, Inc. (NASDAQ:NEO) Fundamentals That Matter

It’s generally a good idea to start with the most fundamental piece of the picture: the balance sheet. The balance sheet health of any company plays a key role in its ability to meet its obligations and maintain the faith of its investment base. For NEO, the company currently has 15.17 million of cash on the books, which is offset by 10.21 million in current liabilities. The trend over time is important to note. In this case, the company’s debt has been falling. The company also has 349.27 million in total assets, balanced by 141.26 million in total liabilities, which should give you a sense of the viability of the company under any number of imagined business contexts.

NeoGenomics, Inc. (NEO) saw 9.65 million in free cash flow last quarter, representing a quarterly net change in cash of 2.35 million. Perhaps most importantly where cash movements are concerned, the company saw about 14.31 million in net operating cash flow.

NeoGenomics, Inc. (NASDAQ:NEO) Revenue Growth Potential

As far as key trends that demonstrate something of the future investment potential of this stock, we need to take a closer look at the top line, first and foremost. Last quarter, the company saw 63.42 million in total revenues. That represents a quarterly year/year change in revenues of 0.03 in sequential terms, the NEO saw sales decline by -0.06.

But what about the bottom line? After all, that’s what really matters in the end. NeoGenomics, Inc. (NEO) is intriguing when broken down to its core data. The cost of selling goods last quarter was 37.53 million, yielding a gross basic income of 25.89 million. For shareholders, given the total diluted outstanding shares of 80.51 million, this means overall earnings per share of -0.03. Note, this compares with a consensus analyst forecast of 0.02 in earnings per share for its next fiscal quarterly report.

Is NeoGenomics, Inc. (NASDAQ:NEO) Valuation Attractive

Looking ahead at valuations, according to the consensus, the next fiscal year is forecast to bring about 0.20 in total earnings per share. If we consider a median price to earnings ratio on the stock, that corresponds with a stock price of 50.83. However, one should always remember: the trends are more important than the forecasts. This continues to be an interesting story, and we look forward to updating it again soon on NeoGenomics, Inc..

Previous ArticleNext Article

Related Post

Checking Out the Fundamental Data for Organovo Hol... Organovo Holdings, Inc. (NASDAQ:ONVO) has recently been identified as an interesting stock but more in-depth monitoring is needed for a trade decision...
Looking at the Big Picture for The Goldman Sachs G... The Goldman Sachs Group, Inc. (NYSE:GS) seems to be forming a pattern of major movements, providing only some crumbs of outlook for market participant...
How Does the Fundamental Picture Look for Facebook... It's worth it to have a look at Facebook, Inc. (NASDAQ:FB) as there may be a chasm between the bulls and the bears as far as recent trading activity g...
Cenovus Energy Inc. (CVE): Trading Secrets for Tod... Cenovus Energy Inc. (NYSE:CVE) fell by -3.50% in trading on Monday from $8.01 to $7.73.  The price has fallen in 6 of the last 10 days and is down by ...
Bellicum Pharmaceuticals, Inc. (BLCM): How Do the ... Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) is in the highlights and many would want to know whether now might be a good time for it to present much ...